A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR …
Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of …
C Gridelli, A Rossi, F Ciardiello, F De Marinis… - Clinical Lung Cancer, 2016 - Elsevier
Background About 20% of advanced non–small-cell lung cancer (NSCLC) cases harbor
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - 2018 - ascopubs.org
9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm …
R Rosell, U Dafni, E Felip… - The Lancet …, 2017 - thelancet.com
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer …
T Kato, T Seto, M Nishio, K Goto, S Atagi, Y Hosomi… - 2014 - ascopubs.org
8005 Background: Despite the development of EGFR tyrosine kinase inhibitors, median
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …
Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results
T Kato, T Seto, M Nishio, K Goto, N Yamamoto… - Drug safety, 2018 - Springer
Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …